Yong Zhang

Company: Intellia Therapeutics

Job title: Senior Director

Seminars:

Leveraging Cell Engineering to Maximize Anti-Tumor Properties of Allogeneic Cells 12:00 pm

Intellia’s differentiated allogeneic platform has shown key characteristics in in vitro assays and in vivo mouse models Approach expected to be compatible with standard lymphodepletion Allogeneic platform is readily deployable for TCR-T and CAR-T cell therapyRead more

day: Day One - Track A AM